Selective inhibition of ERO1α with M6766, a novel small-molecule inhibitor, prevents arterial thrombosis and ischemic stroke in mice
Molecular Therapy · 2025-10 · 33 (10) · 5177-5191
DOI: 10.1016/j.ymthe.2025.07.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025-10. Verfasst von Jinzhi Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Thrombosis, Ischemic Stroke, Small Molecule Libraries, Enzyme Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, National Institutes of Health.
Themen: Schlaganfall
Abstract (Originalsprache)
Using endoplasmic reticulum oxidoreductase 1α (ERO1α) conditional knockout (CKO) mice, a recent study underscores the crucial role of ERO1α in platelet activation under thrombotic conditions. Through a high-throughput screen of 39,901 compounds, we identify M6766 as a selective inhibitor of ERO1α with an IC50 of 1.4 μM and a KD of 1.1 μM. A docking model and biochemical studies reveal that M6766 binds to the flavin adenine dinucleotide-binding pocket in ERO1α and exhibits >70-fold selectivity over other tested enzymes, except ERO1β, which it inhibits with an IC50 of 7.2 μM. M6766 concentration-dependently inhibits granule secretion, αIIbβ3 integrin activation, Ca2+ mobilization, and platelet aggregation induced by various agonists, but it does not affect agonist-induced production of reactive oxygen species. Pretreatment of ERO1α with M6766 reduces its binding to the Ca2+ sensor stromal interaction molecule 1. To validate whether these inhibitory effects result from the inhibition of ERO1α and ERO1β, we generate megakaryocyte-specific Ero1β or Ero1α/β CKO mice. Deletion of platelet Ero1α/β impairs platelet activation and aggregation, whereas deletion of Ero1β has no effect. While EN460 markedly inhibits the function of Ero1α/β-null platelets, M6766 does not, highlighting its specificity. M6766 treatment diminishes platelet accumulation on collagen-coated surfaces under arterial shear conditions. Moreover, intravenous injection of M6766 into mice decreases arterial thrombosis and infarct volume during ischemic stroke without prolonging tail bleeding times. Although eptifibatide, an αIIbβ3 antagonist, effectively blocks arterial thrombosis, it prolongs bleeding times at therapeutic doses. Our findings suggest that ERO1α inhibition is a promising anti-thrombotic strategy with potential advantages over current therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Division of Endocrinology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Center for Drug Discovery, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
- Vascular Medicine Institute, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15213, USA; Pittsburgh VA Medical Center, Pittsburgh, P…
- Division of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO 63110,…
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- National Institutes of Health
- National Heart Lung and Blood Institute
- National Institute of Allergy and Infectious Diseases
- American Heart Association
Zitieren
APA
Wang, J., Kim, J. S., Jha, V., Brown, G., Lee, J., Bokorova, R., Jin, B. R., Ahmed, M., Castelblanco, E., Johnson, D., Prinsen, M., Ilagan, M. X. G., Remedi, M. S., Razani, B., Dolle, R. E., & Cho, J. (2025). Selective inhibition of ERO1α with M6766, a novel small-molecule inhibitor, prevents arterial thrombosis and ischemic stroke in mice. Molecular Therapy, 33(10), 5177-5191. https://doi.org/10.1016/j.ymthe.2025.07.033
Vancouver
Wang J, Kim JS, Jha V, Brown G, Lee J, Bokorova R, et al. Selective inhibition of ERO1α with M6766, a novel small-molecule inhibitor, prevents arterial thrombosis and ischemic stroke in mice. Molecular Therapy. 2025;33(10):5177-5191. doi:10.1016/j.ymthe.2025.07.033
BibTeX
@article{Wang2025,
author = {Wang, Jinzhi and Kim, Jae-Sung and Jha, Vishwanath and Brown, Gavriel and Lee, Jingu and Bokorova, Radka and Jin, Bo-Ram and Ahmed, Muteen and Castelblanco, Esmeralda and Johnson, Daniel and Prinsen, Michael and Ilagan, Ma Xenia G and Remedi, Maria S and Razani, Babak and Dolle, Roland E and Cho, Jaehyung},
title = {Selective inhibition of ERO1α with M6766, a novel small-molecule inhibitor, prevents arterial thrombosis and ischemic stroke in mice},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {10},
pages = {5177--5191},
doi = {10.1016/j.ymthe.2025.07.033}
}
EUVIMED